Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deciphera’s Vimseltinib Could Benefit From Liver Safety, Prescriber Overlap in TGCT

Executive Summary

Positive topline results from the Phase III MOTION trial showed none of the liver toxicity that earned Daiichi Sankyo’s Turalio a boxed warning and REMS in tenosynovial giant cell tumor.

You may also be interested in...



Multiple Firsts As Pexidartinib Approved In US - With Warning

Further progress for Daiichi Sankyo's strategic push into oncology as US issues first approval globally for first-in-class rare disease drug Turalio - but with liver toxicity safeguards.

Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines

Shah Capital Management said Novavax could tap the estimated 100 million Americans uncomfortable with mRNA vaccines, such as those from Pfizer/BioNTech and Moderna.

Novartis Expands In Protein Degradation, Complements Radioligand Platform With Arvinas Deal

Deal Snapshot: The company told Scrip that part of why it licensed Arvinas’s ARV-766 and took over AR-V7 was to complement its radioligand therapy platform in prostate cancer.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel